(Q31032833)

28 June 2017

1 reference

title

Terazosin, doxazosin, and prazosin: current clinical experience (English)

1 reference

28 June 2017

Akduman B

1

1 reference

28 June 2017

Crawford ED

series ordinal

2

1 reference

28 June 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

28 June 2017

1 reference

28 June 2017

volume

58

1 reference

28 June 2017

issue

6 Suppl 1

1 reference

28 June 2017

page(s)

49-54

1 reference

The economics of benign prostatic hyperplasia treatment: a literature review.

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Benign prostatic hyperplasia: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

The development of human benign prostatic hyperplasia with age

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Management of symptomatic BPH in the US: who is treated and how?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

A Placebo-controlled Double-blind Study of the Effect of Phenoxybenzamine in Benign Prostatic Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Benign prostatic hyperplasia. Medical and minimally invasive treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

This month in investigative urology: alpha adrenergic innervation of the prostate: insights into pharmacotherapy of BPH

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Comprehensive patient evaluation for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Modulation of the differentiation status of cultured prostatic smooth muscle cells by an alpha1-adrenergic receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Alpha-blockers and lower urinary tract function: more than smooth muscle relaxation?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Prazosin in the Treatment of Prostatic Obstruction A Placebo-controlled Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Adverse effects of alpha 1-adrenergic blocking drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901302-4

7 January 2021

10.1016/S0090-4295(01)01302-4

Identifiers

DOI

1 reference

28 June 2017

1 reference